Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Ossianix Inc. is currently managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 2 actions are distributed among 2 distinct examiners and 2 distinct art units. This distribution indicates that the company's active prosecution is not centralized, as each pending matter is being reviewed by a different examiner in a different art unit.
CRAIG, KAILA ANGELIQUE is the busiest examiner for the portfolio, holding 1 pending office action. This action is part of the 2 total pending office actions for the company. The presence of 2 distinct art units suggests that the applicant must tailor responses to the specific examination standards of two separate administrative groups within the USPTO.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CRAIG, KAILA ANGELIQUE | 1 | 34.8% | +24.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18448332 | IN VIVO METHODS FOR SELECTING PEPTIDES THAT CROSS THE BLOOD BRAIN BARRIER, RELATED COMPOSITIONS AND METHODS OF USE | CRAIG, KAILA ANGELIQUE | — |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18448332 | IN VIVO METHODS FOR SELECTING PEPTIDES THAT CROSS THE BLOOD BRAIN BARRIER, RELATED COMPOSITIONS AND METHODS OF USE | CRAIG, KAILA ANGELIQUE | 1618 | §103 | Non-Final OA | — | Pending | Aug 11, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOssianix Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Kaila Angelique Craig has the most, with 1 of Ossianix Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.